共 48 条
[1]
Boguniewicz M(2018)Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape Ann Allergy Asthma Immunol 120 10-22.e12
[2]
Fonacier L(2019)Exploring content and psychometric validity of newly developed assessment tools for itch and skin pain in atopic dermatitis J Patient Rep Outcomes 3 42-706.e2697
[3]
Guttman-Yassky E(2019)Pain is a common and burdensome symptom of atopic dermatitis in United States adults J Allergy Clin Immunol Pract 7 2699-52.e543
[4]
Ong PY(2017)Burden of skin pain in atopic dermatitis Ann Allergy Asthma Immunol 119 548-1379
[5]
Silverberg J(2019)Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial JAMA Dermatol 155 1371-S61
[6]
Farrar JR(2021)Patient-reported symptoms and disease impacts in adults with moderate-to-severe atopic dermatitis: results from a phase 2b study with abrocitinib Dermatitis 32 S53-1112
[7]
Newton L(2021)Abrocitinib versus placebo or dupilumab for atopic dermatitis N Engl J Med 384 1101-873
[8]
DeLozier AM(2020)Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial JAMA Dermatol 156 863-266
[9]
Griffiths PC(2020)Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial Lancet 396 255-1788
[10]
Silverberg JI(2018)Evaluation of a Janus kinase 1 inhibitor, PF-04965842, in healthy subjects: a phase 1, randomized, placebo-controlled, dose-escalation study Br J Clin Pharmacol 84 1776-467